{"id":"NCT02681094","sponsor":"AstraZeneca","briefTitle":"A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes","officialTitle":"A Multi-Center, Randomized, Double-Blind, Active-Controlled , Parallel Group, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin 5mg Co-administered With Dapagliflozin 5mg Compared to Saxagliptin 5mg or Dapagliflozin 5mg All Given as Add-on Therapy to Metformin inPatients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Alone","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-02-26","primaryCompletion":"2017-07-15","completion":"2017-07-15","firstPosted":"2016-02-12","resultsPosted":"2018-10-10","lastUpdate":"2018-10-10"},"enrollment":905,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus","Inadequate Glycaemic Control"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Forxiga"]},{"type":"DRUG","name":"Placebo for Dapagliflozin","otherNames":[]},{"type":"DRUG","name":"Saxagliptin","otherNames":["Onglyza™"]},{"type":"DRUG","name":"Placebo for Saxagliptin","otherNames":[]}],"arms":[{"label":"Saxagliptin+Dapagliflozin+Metformin","type":"ACTIVE_COMPARATOR"},{"label":"Dapagliflozin+Saxagliptin placebo+Metformin","type":"ACTIVE_COMPARATOR"},{"label":"Saxagliptin+Dapagliflozin placebo+metformin","type":"ACTIVE_COMPARATOR"}],"summary":"The aim of this study is to evaluate safety and efficacy of therapy with saxagliptin 5mg co-administered with dapagliflozin 5mg, compared to therapy with saxagliptin 5mg or dapagliflozin 5mg in patients who are inadequately controlled on ≥1500mg/day of metformin monotherapy.","primaryOutcome":{"measure":"Change From Baseline in HbA1c at Week 24","timeFrame":"Baseline and week 24","effectByArm":[{"arm":"Dapagliflozin + Saxagliptin + Metformin","deltaMin":-1.03,"sd":0.0558},{"arm":"Dapagliflozin + Metformin","deltaMin":-0.63,"sd":0.056},{"arm":"Saxagliptin + Metformin","deltaMin":-0.69,"sd":0.0551}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":110,"countries":["United States","Canada","Czechia","Germany","Mexico","Russia"]},"refs":{"pmids":[],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3863&filename=d1683c00005_csp_Redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=3863&filename=D1683C00005_SAP_redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":293},"commonTop":["Glomerular filtration rate decreased","Viral upper respiratory tract infection","Urinary tract infection","Influenza","Nausea"]}}